This work reports a newly designed pH-activatable and aniline-substituted aza-boron-dipyrromethene as a trifunctional photosensitizer to achieve highly selective tumor imaging, efficient photodynamic therapy (PDT) and therapeutic self-monitoring through encapsulation in a cRGD-functionalized nanomicelle. The diethylaminophenyl is introduced in to the structure for pH-activatable near-infrared fluorescence and singlet oxygen ( 
Introduction
In current cancer research, the design of a theranostic agent that combines diagnosis and therapy into a single platform offers exciting prospects for the development of personalized medicine.
1 Many well established photosensitizers of the rst, second and third generation 2a have been used for the construction of theranostic agents.
2 These are generally nontoxic in their native state, however, under irradiation with the appropriate wavelength and power, they can transfer the absorbed photon energy to the surrounding molecular oxygen ( 3 O 2 ), generating cytotoxic singlet oxygen ( 1 O 2 ) to kill cancer cells. 3 This technology is well known as photodynamic therapy (PDT) and has been largely used for the treatment of many localized supercial cancers.
3 Meanwhile, upon light excitation, the photosensitizer can uoresce for tumor diagnosis, location and image-guided therapy.
4 Furthermore, by measuring the uorescence photobleaching of the photosensitizer, or the detection of 1 O 2 phosphorescence emission during the PDT process, 5 the light dose in the PDT can be accurately administered to prevent under-or over-illumination.
Recently, photosensitizers have been integrated in various nanomaterials including magnetic nanoparticles, 6 quantum dots, 7 gold vesicles, 8 upconversion nanoparticles 9 and graphene oxide nanosheets 10 to construct highly efficient theranostic agents. While these agents show encouraging treatment results, there are still three main limitations. The inorganic or metallic nature of most of the nanomaterials has raised great concern about their potential toxicity to normal tissues. To solve this problem, polymer-based materials such as poly (lactic acid) and poly(ethylene oxide) with good biocompatibility are desired because they are typically nontoxic and degraded naturally into safe materials in the body over time.
11
Another problem is the always-on property of photosensitizers which leads to a high background uorescence and therapeutic side effects. An efficient way to overcome this problem is to design the photosensitizer with activatable functionality.
12
The photosensitizer should be switched off in noncancerous tissues but can be switched on by specic cancer-associated stimuli to effectively produce uorescence and 1 O 2 . The third problem is that most currently available photosensitizers absorb visible light with limited penetration. Developing a novel photosensitizer with a strong absorbance in the near-infrared (NIR, 700-1000 nm) region can effectively solve this problem, 13 which improves the homogeneity of the photosensitizer. These limitations and challenges have driven the further design of novel multifunctional photosensitizers and theranostic agents.
Our previous work reported a nanomicelle as a theranostic agent for simultaneous cancer imaging, PDT and therapeutic monitoring.
14 However, the uorescence excitation wavelength was less than 700 nm for monitoring therapeutic efficacy and the photosensitizer was always-on for 1 O 2 generation limiting its application. In this regard, we attempt to rationally design a pH-activatable, NIR photosensitizer for the preparation of theranostic agents. Herein, this goal is realized using a newly designed trifunctional photosensitizer, NEt 2 Br 2 BDP, which features an aza-boron-dipyrromethene (aza-BODIPY) structure substituted with diethylaminophenyl and bromophenyl (Fig. 1a) . For in vivo application, NEt 2 Br 2 BDP is encapsulated in a cyclic RGD peptide-poly(ethylene glycol)-block-poly(lactic acid) (cRGD-PEG-PLA) and methoxyl poly(ethylene glycol)-block-poly(lactic acid) (mPEG-PLA) nanomicelle to form a theranostic nanoprobe (cRGD-NEt 2 Br 2 BDP NP). The nanoprobe is silent at pH 7.4 in a physiological environment. With the help of the cRGD, it can be selectively taken up by a v b 3 integrin-rich tumor cells into the lysosomes. In these, the nanoprobe is activated by the acidic environment at pH 4.5-5.0 to produce uorescence at 925 nm for tumor discrimination, and 1 O 2 for tumor therapy, under 808 nm irradiation. In addition, therapeutic self-monitoring can be achieved synchronously by monitoring the decrease of uorescence. This work reports an effective theranostic nanoprobe for highly selective in vivo tumor imaging, efficient PDT and therapeutic self-monitoring in the NIR region. 17 The molecular weights (M w ) of the cRGD-PEG-PLA and mPEG-PLA were determined to be 7.1 and 4.6 kDa respectively by comparing the peak areas of PLA and PEG resonance at 5.20 ppm (-C(]O)-CH(-CH 3 -)) and 3.65 ppm (-OCH 2 CH 2 -) in 1 H NMR spectra ( Fig. S2 and S3 †) , respectively. The encapsulation efficiency (EE) and loading efficiency (LE) was measured to be 84.8% and 3.2%, respectively (Table S1 †). The TEM image of cRGD-NEt 2 Br 2 BDP NP showed a well-dispersed spherical morphology with core-shell structure (Fig. 1b) . Its average hydrodynamic diameter, measured by dynamic light scattering (DLS), was 138.4 AE 17.3 nm (Fig. 1b) , which did not change for at least four weeks (Fig. S4 †) , indicating the colloidal stability of the nanoprobe. Aer encapsulation in the nanomicelle, the absorption of NEt 2 Br 2 BDP was maintained well (Fig. 1c) , indicating the structural integrity. The 10 nm red shi of the absorption peak of cRGD-NEt 2 Br 2 BDP NP in PBS compared with those of both free NEt 2 Br 2 BDP and cRGD-NEt 2 Br 2 BDP NP in CHCl 3 (Fig. S5 †) was attributed to the entrapment of NEt 2 Br 2 BDP inside the core of the nanomicelle.
Results and discussion
18 The cRGD-NEt 2 Br 2 BDP NP could be excited at the NIR region to produce a NIR uorescence emission at 925 nm which was highly pH-dependent (Fig. 1d) . The uorescence at 925 nm was almost undetectable at pH 7.4 with a uorescence quantum yield F F of less than 0.002 using indocyanine green (ICG) in DMSO (F F ¼ 0.13) as a standard (see ESI †). The uorescence quenching was due to the photoinduced electron transfer from the aniline moiety to the excited uorophore.
19 With the increase of solution acidity, the uo-rescence at 925 nm increased distinctly, which produced a F F of 0.18 at pH 4.5. The maintained absorption and pH-dependent uorescence of the probe indicated a porous structure, which ensured the access of protons to NEt 2 Br 2 BDP. The standard uorescence pH titration gave an apparent pK a value of 5.2 (Fig. 1e) , which suggested that the cRGD-NEt 2 Br 2 BDP NP was pH activatable and could respond to a physiologically acidic pH range of 4. 5-6.9 (ref. 20) with high sensitivity. Upon 635 nm excitation, the cRGD-Br 2 BDP NP uoresced at 685 nm ( Fig. S6 †) , and was stable to the solution pH (Fig. 1e) , indicating that cRGD-Br 2 BDP NP could be used as an always-on control. In contrast to the designed cRGD-NEt 2 Br 2 BDP NP, the pHdependent uorescence of cRGD-NMe 2 Br 2 BDP NP occurred at 910 nm ( Fig. S7 †) , and showed a pK a value of 4.1 (Fig. 1e) , not matching the physiologically acidic pH range. Thus cRGDNMe 2 Br 2 BDP NP was used as an always-off control. Aer exposing the mixed cRGD-NEt 2 Br 2 BDP NP and SOSG solution at pH 7.4 to 808 nm irradiation for 300 s, the SOSG uorescence intensity at 525 nm did not increase, while the uorescence intensity of SOSG increased greatly at pH 5.0 under 808 nm irradiation ( Fig. S8 -S10 †). The SOSG intensity increased 11 fold from pH 5.0 to 7.4 (Fig. 1f) . The singlet oxygen quantum yields (F D ) of cRGD-NEt 2 Br 2 BDP NP at different pHs could be measured using a 1,3-diphenylisobenzofuran (DPBF) method (Fig. S11 †) . 19 The results indicated that the F D increased from 0.05 at pH 7.4 to 0.56 at pH 5.0, which further conrmed the pH controllable release of 1 O 2 . The always-on cRGD-Br 2 BDP NP or always-off cRGD-NMe 2 Br 2 BDP NP controls showed negligible pH impact on the SOSG uorescence intensity aer irradiation (Fig. 1f) . These results demonstrated that cRGD-NEt 2 Br 2 BDP NP was a potential and promising pH-activatable theranostic agent for cancer treatment.
Sensitivity of cRGD-NEt 2 Br 2 BDP NP-based NIR imaging
NIR uorescence facilitates bioimaging and detection because it is less susceptible to interference from tissue autouorescence. 21 The sensitivity of the cRGD-NEt 2 Br 2 BDP NPbased uorescence imaging was studied in BALB/c nude mice ( Fig. 2a) . The a v b 3 integrin-rich human glioblastoma U87MG tumor cells were used as a model and labelled with cRGDNEt 2 Br 2 BDP NP. Aer 500, 200 and 50 cRGD-NEt 2 Br 2 BDP NPlabelled U87MG cells were subcutaneously injected into the back of a nude mouse, the mouse was subjected to imaging on a Maestro EX in vivo imaging system. The U87MG cells displayed distinct uorescence at the injection sites while no uorescence signals were observed in other regions of the mouse body. The detectable cell number down to 50 cells, lower than the detection limit of 98 cells of infrared-emitting long-persistence luminescent nanoparticles-based cell tracking, 22 was clearly visualized, revealing good sensitivity. The sensitivity was attributed to the use of NIR uorescence as this is less susceptible interference from tissue autouorescence. The penetrability of NIR uorescence was further examined with a mouse treated with an intralumen injection of cRGD-NEt 2 Br 2 -BDP NP-labelled U87MG cells (Fig. 2b) , which indicated that the NIR uorescence could penetrate through the thoracic cavity of the live nude mouse and was detectable on its back. The thickness of the mouse body was about 2 cm, and the penetration depth of the pH activatable cRGD-NMe 2 Br 2 BDP NP was at least 1 cm. These results conrmed that the excitation and emission light of the nanoprobe possessed acceptable penetration depth for the imaging of tumor cells.
In vivo imaging on subcutaneous U87MG tumor-bearing mice
The blood circulation curve of cRGD-NEt 2 Br 2 BDP NP in mice showed the biphasic clearance prole with a rapid clearance during the rst 5 h followed by a continuous and slow elimination rate (Fig. S12 †) . The blood circulation half-life was found to be 4.8 h, indicating a long persistence of cRGD-NEt 2 Br 2 BDP NP in the bloodstream to corroborate its stability in vivo. The in vivo tumor imaging was investigated in mice bearing a subcutaneous U87MG tumor xenogra. The U87MG tumor-bearing mice were intravenously injected with cRGD-NEt 2 Br 2 BDP NP, cRGD-NMe 2 Br 2 BDP NP or cRGD-ICG NP, and subjected to in vivo imaging at different time points to explore the function of pH activation (Fig. 3a) .
To explore the targeting effect of cRGD, the U87MG tumorbearing mice were also injected intravenously with NEt 2 Br 2 BDP NP without cRGD functionalization and subjected to imaging (Fig. 3b) . As an additional control, a blocking dose of cRGD was injected before the cRGD-NEt 2 Br 2 BDP NP administration in one mouse (Fig. 3b) . Two hours aer injection, the tumor tissue in the cRGD-NEt 2 Br 2 BDP NP-treated mouse could be distinguished from the surrounding normal tissues (Fig. 3a) . The ratio of uorescence at tumor to normal tissue (T/N tissue ratio) increased gradually and reached a maximum (10 fold) at 8 h postinjection, and a high uorescence contrast could be maintained even 16 h aer postinjection (Fig. 3c) , demonstrating the targeted delivery, pH-activatable uorescence and long retention of cRGD-NEt 2 Br 2 BDP NP in tumor tissue. Ex vivo imaging clearly showed that the specic activation of cRGDNEt 2 Br 2 BDP was at the tumor tissue over other organs including heart, liver, spleen, lung, kidney, stomach, intestine and muscle (Fig. S13 †) . Conversely, the always-off cRGD-NMe 2 Br 2 BDP NP treated mouse, which was used as a negative control, showed negligible uorescence in the tumor (Fig. 3a) and other organs (Fig. S14 †) . This could be explained by the pK a of 4.1 of this photosensitizer resulting in the inactivation of cRGD-NMe 2 -Br 2 BDP NP. For the always-on cRGD-ICG NP treated mouse, used as a positive control, although the tumor displayed uo-rescence, the interferences from normal tissues were serious (Fig. 3a) , and the high uorescence background was also observed in lung, liver and kidneys (Fig. S15 †) , leading to a low T/N tissue ratio (less than 0.8) at all time points (Fig. 3c) . Compared to the always-off cRGD-NMe 2 Br 2 BDP NP and alwayson cRGD-ICG NP, the 10 fold T/N tissue ratio veried the advantages of the pH-activatable function of cRGD-NEt 2 Br 2 BDP NP by reducing the signal background from the normal tissues. For the NEt 2 Br 2 BDP NP and free cRGD competition controls, no uorescence was observed in tumor (Fig. 3b) , which conrmed the contribution of cRGD in tumor targeting for pH activation.
In vivo PDT evaluation
For in vivo PDT treatment, the U87MG tumor-bearing mice were randomly divided into 6 groups of the untreated mice (group 1), treated with irradiation (group 2), cRGD-NEt 2 Br 2 BDP NP injected (group 3), cRGD-NEt 2 Br 2 BDP NP injected and then treated with irradiation (group 4), NEt 2 Br 2 BDP NP injected and then irradiated (group 5), or cRGD-NMe 2 Br 2 BDP NP injected and then irradiated (group 6). 8 h aer injection, the corresponding treatment was conducted. The irradiation was performed with a NIR 808 nm laser at an irradiance of 100 mW cm À2 for 300 s.
The therapeutic effects aer treatment were assessed by monitoring the change of relative tumor volumes ( Fig. 4a ) and hematoxylin and eosin (H&E) staining (Fig. 4b) . No tumor growth inhibition or tumor tissue necrosis was observed in the group of mice in the absence of irradiation and/or cRGD-NEt 2 -Br 2 BDP NP, which indicated that irradiation with a low irradiance of 100 mW cm À2 had little photothermal effect and the cRGD-NEt 2 Br 2 BDP NP had little dark toxicity. In marked contrast, the tumor growth for group 4 was remarkably suppressed, and the tumor tissue showed obvious necrosis, indicating that cRGD-NEt 2 Br 2 BDP NP could be effectively activated under NIR irradiation to produce a strong phototoxicity to the tumor. Group 5 did not show a therapeutic effect in tumor tissue due to the lack of cRGD targeting for pH activation, and group 6 showed rapid tumor growth because the cRGD-NMe 2 -Br 2 BDP NP could not be activated by physiologically acidic pH under irradiation. These results conrmed the high therapeutic effect of cRGD-NEt 2 Br 2 BDP NP-mediated PDT. The potential toxicity or side effects are always a great concern for theranostic agents used in medicine. At the cellular level, the NEt 2 Br 2 BDP before and aer irradiation showed negligible toxicity (Fig. S16 †) . The mice treated with the NPmediated PDT did not show apparent body weight loss (Fig. S17 †) . At 12 days aer treatment, the PDT-treated mice and the age-matched healthy mice without treatment were sacriced, and the major organs including heart, liver, spleen, lung, and kidney were collected for H&E staining to evaluate toxic effect. No noticeable sign of organ damage was observed on the H&E-stained organ slices (Fig. S18 †) , which suggested the safety of cRGD-NEt 2 Br 2 BDP NP for in vivo PDT application.
Therapeutic mechanism of cRGD-NEt 2 Br 2 BDP NP-mediated PDT
In order to understand the therapeutic mechanism down to the subcellular level, the cRGD-NEt 2 Br 2 BDP NP-loaded U87MG cells were incubated with SOSG to study the subcellular localization of 1 O 2 . Aer 808 nm irradiation, strong SOSG uorescence was observed which overlapped with the LysoTracker Red (Fig. 4c) , suggesting that 1 O 2 generation occurred in the lysosomes.
Previous work had demonstrated that 1 O 2 production in the lysosome induced lysosomal membrane permeabilization and subsequent release of cathepsins into cytosol to trigger celldeath pathways. 14, 19 To further conrm the lysosomal destruction, acridine orange (AO) was employed as an integrity indicator of lysosomes, which emits red uorescence in lysosomes and green uorescence in the cytosol and nuclei. 23 The lysosomes in the U87MG cells displayed bright red uorescence in the absence of cRGD-NEt 2 Br 2 BDP NP and/or irradiation (Fig. 4d) , suggesting that the lysosomal compartments were intact. Aer the cRGD-NEt 2 Br 2 BDP NP-loaded cells were irradiated, the red AO uorescence disappeared (Fig. 4d) , which indicated the destruction of the lysosomal membrane. Aer the U87MG cells were treated with the always-off cRGD-NMe 2 Br 2 -BDP NP, the irradiation with a 808 nm laser did not damage the lysosomes (Fig. S19a †) , which excluded the photothermal effect during irradiation. Moreover, the addition of vitamin C as a 1 O 2 scavenger could efficiently prevent the damage to the lysosomes (Fig. S19b †) . Therefore, the generated 1 O 2 from the cRGDNEt 2 Br 2 BDP NP-mediated PDT induced the cell death in a lysosome-associated pathway.
Therapeutic self-monitoring
Owing to the intrinsic property of the pH-activatable uores-cence of cRGD-NEt 2 Br 2 BDP NP, the function of therapeutic selfmonitoring during the PDT process could be realized by uo-rescence imaging (Fig. 5a ). Two groups of mice bearing U87MG tumors were intravenously injected with the nanoprobe. 8 h aer the injection, they displayed a T/N tissue ratio of more than 10 fold (Fig. 5b) . With the pH-activatable uorescence guiding, the group of mice was irradiated with an 808 nm laser at 100 mW cm À2 for 300 s, and another group of mice was kept in the dark as a control. Aer irradiation, the therapeutic selfmonitoring was performed by observing the uorescence change of cRGD-NEt 2 Br 2 BDP NP. The uorescence intensity from the irradiated tumor decreased gradually (Fig. 5a ) and almost disappeared with a 1.4 fold T/N tissue ratio aer 12 h (Fig. 5b) . In contrast, the changes in both uorescence (Fig. 5a ) and T/N tissue ratio (Fig. 5b) for the unirradiated tumor were negligible over the same period. In order to investigate the physiological transformation along with the uorescence change aer PDT, H&E staining of the two tumors was performed. Prominent necrosis was observed in the PDT-treated tumor tissue, while necrosis was indiscernible in the unirradiated tumor (Fig. 5c) . Therefore, the cRGD-NEt 2 Br 2 BDP NP displayed not only highly selective tumor imaging and effective therapy functions, but also a self-monitoring capability for the evaluation of therapeutic efficacy.
Experimental section
Preparation and characterization of cRGD-NEt 2 Br 2 BDP NP An emulsion/solvent evaporation method was used for the preparation of cRGD-NEt 2 Br 2 BDP NP. 14 In brief, 21 mg of cRGD-PEG-PLA and mPEG-PLA copolymers with a mixing ratio of 5% (w/w%) and 0.8 mg of NEt 2 Br 2 BDP were dissolved in 2 mL of CH 2 Cl 2 , which was then added to 4 mL of 2% Pluronic® F-127 aqueous solution. The mixture was sonicated using a probe sonicator (Scientz Biotechnology Co. Ltd, China) for 30 s at 180 W output. The formed emulsion was added dropwise to 20 mL of a magnetically stirred 0.5% Pluronic® F-127 aqueous solution. Aer stirring for 1 h, the remaining organic solvent was removed in a rotary evaporator at reduced pressure at 30 C. The cRGD-NEt 2 Br 2 BDP NP solution was ltrated through a Millipore syringe lter (pore size 0.45 mm) to remove unencapsulated NEt 2 Br 2 BDP aggregates and further puried by centrifugation at 21 000Âg for 15 min using a centrifugal lter with cutoff M w of 100 kDa (Millipore, MA). Aer purication the cRGD-NEt 2 Br 2 -BDP NP solution was freeze-dried. Similar procedures were used to prepare the cRGD-Br 2 BDP NP, cRGD-NMe 2 Br 2 BDP NP, cRGD-ICG NP and NEt 2 Br 2 BDP NP, in which the nanocarrier was composed of mPEG-PLA. The EE and LE of the photosensitizer loaded in the cRGD functionalized nanomicelles were determined by UV-VIS-NIR absorption spectroscopy. The EE and LE were expressed according to the following formulas: EE (%) ¼ ((weight of loaded photosensitizer)/(weight of initially added photosensitizer)) Â 100; LE (%) ¼ ((weight of loaded photosensitizer)/(total weight of nanomicelle)) Â 100. DLS and TEM measurements were performed to examine the size distribution and morphology of cRGD-NEt 2 Br 2 BDP NP.
In vivo tumor imaging
All animal operations were in accord with institutional animal use and care regulations approved by the Model Animal Research Center of Nanjing University (MARC). Specic pathogen-free (SPF) BALB/c nude mice, 5-6 weeks of age, were purchased from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (SLACCAS) and bred in an axenic environment. Glioblastoma tumor models were established in BALB/c nude mice by injecting 1 Â 10 6 U87MG cells subcutaneously into the selected positions. Tumors were then allowed to grow to 8-10 mm in diameter. For the blood circulation time assay of cRGD-NEt 2 Br 2 BDP NP, the mice were fasted but had free access to water for 16 h, and were then intravenously injected with 20 mg kg À1 cRGD-NEt 2 Br 2 BDP NP via tail vein.
Aer injection for 0.5, 1, 3, 6, 12, 24 and 48 h, these mice were sacriced, respectively, and the blood samples were obtained. With a standard curve method, the blood circulation time of the cRGD-NEt 2 Br 2 BDP NP was determined by measuring the uo-rescence of cRGD-NEt 2 Br 2 BDP NP under acidic condition. To demonstrate the contribution of pH activation, 20 mg kg À1 pHactivatable cRGD-NEt 2 Br 2 BDP NP, always-off cRGD-NMe 2 Br 2 -BDP NP or always-on cRGD-ICG NP was intravenously injected into the U87MG tumor-bearing mice (n ¼ 6) via a tail vein. In vivo tumor imaging was then performed on a Maestro EX in vivo imaging system with an excitation of 735 nm and collected emission range of 800-950 nm at 2, 4, 8 and 16 h postinjection. At 24 h postinjection, the mice were euthanized to obtain the organs and tumor tissues for imaging. To elucidate the role of a v b 3 -mediated endocytosis, a group of mice (n ¼ 6) were intravenously injected with 20 mg kg À1 NEt 2 Br 2 BDP NP at 8 h and another group of mice (n ¼ 6) were intravenously injected with cRGDyk (25 mg kg À1 ) 30 min before cRGD-NEt 2 Br 2 BDP NP administration. During the injection and image acquisition process, the mice were anesthetized with 2.5% isourane in oxygen delivered at a ow rate of 1.5 L min À1 . T/N tissue ratios were determined by comparing the average uorescence intensities in the tumor and the whole body except the tumor site using Maestro 3.0 soware.
In vivo PDT
In vivo cRGD-NEt 2 Br 2 BDP NP-mediated PDT was performed using U87MG tumor-bearing mice. The mice were randomly divided into 6 groups for the following treatments and each group contained six mice: group 1, untreated; group 2, irradiated with an 808 nm laser for 300 s at an irradiance of 100 mW cm À2 (irradiation); group 3, intravenously injected with 20 mg The mice from different treatment groups were monitored by measuring the tumor volume every two days for 12 days aer treatment. The greatest longitudinal diameter (length) and the greatest transverse diameter (width) of each tumor were determined using a vernier caliper, and the tumor volume was calculated using length Â width 2 Â 0.5.
24
In vivo therapeutic self-monitoring
For self-monitoring of therapeutic efficacy, two groups of mice bearing U87MG tumors were intravenously injected with 20 mg kg À1 cRGD-NEt 2 Br 2 BDP NP via a tail vein. 8 h postinjection, one group of mice (n ¼ 6) was irradiated with an 808 nm laser at an irradiance of 100 mW cm À2 for 300 s and another group of mice (n ¼ 6) was kept in the dark as a control. The therapeutic monitoring was performed in vivo by observing the uorescence change aer irradiation by a Maestro EX in vivo imaging system. The mice were sacriced 24 h aer irradiation to examine the histopathology of the tumors by H&E staining under a BX51 optical microscope (Olympus, Japan) in a blind fashion by a pathologist.
Conclusions
This work reports the successful synthesis of an effective theranostic nanoprobe named cRGD-NEt 2 Br 2 BDP NP to achieve highly selective in vivo tumor imaging, efficient PDT and therapeutic self-monitoring in the NIR region by encapsulating a newly designed trifunctional photosensitizer NEt 2 Br 2 BDP in the cRGD-functionalized nanomicelle. The cRGD-NEt 2 Br 2 BDP NP with little dark toxicity but strong phototoxicity can target to tumor cells via cRGD and be activated by physiologically acidic pH to produce uorescence and 1 O 2 for theranostics. The fascinating advantage of the nanoprobe is the NIR implementation beyond 800 nm, which signicantly improves the imaging sensitivity and increases penetration depth for PDT via a lysosomal cell-death pathway. By monitoring the uorescence decrease in tumor region aer PDT, the therapeutic efficacy is reected in situ and in real time, which provides a valuable and convenient self-feedback function for PDT efficacy tracking. Therefore, this rationally designed and carefully engineered nanoprobe offers a new paradigm for precise tumor theranostics and may provide novel opportunities for future clinical cancer treatment.
